P-glycoprotein - A mediator of multidrug resistance in tumour cells

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 927-944

  Germann, U A ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZIDOPINE; CARRIER PROTEIN; COLCHICINE; CYCLOPEPTIDE; CYTOTOXIC AGENT; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; EMETINE; ETHIDIUM BROMIDE; ETOPOSIDE; FORSKOLIN; GENE PRODUCT; GLYCOPROTEIN P; GRAMICIDIN D; MITHRAMYCIN; PACLITAXEL; PUROMYCIN; QUINIDINE; RAPAMYCIN; RESERPINE; TACROLIMUS; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VALINOMYCIN; VERAPAMIL; VINBLASTINE; VINCRISTINE;

CANCER CELL; CANCER CHEMOTHERAPY; DRUG PROTEIN BINDING; DRUG TRANSPORT; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; REVIEW;

ADENOSINE TRIPHOSPHATASES; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLYCOSYLATION; HUMANS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHOSPHORYLATION;

EID: 0029954843     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00057-3     Document Type: Article

References (280)

1. Beck WT, Danks MK. Characteristics of multidrug resistance in human tumor cells. In Roninson IB, ed. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York, Plenum Publishing Corporation, 1991, 3-46.
2. Sugimoto Y, Tsuruo T. Development of multidrug resistance in rodent cell lines. In Robinson IB, ed. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York, Plenum Publishing Corporation, 1991, 57-70.
3. Kessel D, Botterill V, Wodinsky I. Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Res 1968, 28, 938-941.
4. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970, 30, 1174-1184.
5. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976, 455, 152-162.
6. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 1989, 58, 137-171.
7. Roninson IB, ed. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York, Plenum Publishing Corporation, 1991.
8. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993, 62, 385-427.
9. Chen C-j, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47, 381-389.
10. Hsu SI, Lothstein L, Horwitz SB. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. J Biol Chem 1989, 264, 12053-12062.
11. Devault A, Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990, 10, 1652-1663.
12. Gros P, Croop J, Housman DE. Mammalian multidrug resistance gene: complete cDNA sequence indicate strong homology to bacterial transport proteins. Cell 1986, 47, 371-380.
13. Gros P, Croop J, Roninson IB, Varshavsky A, Housman DE. Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells. Proc Natl Acad Sci USA 1986, 83, 337-341.
14. Endicott JA, Juranka PF, Sarangi F, Gerlach JH, Deuchars KL, Ling V. Simultaneous expression of two P-glycoprotein genes in drug-sensitive Chinese hamster ovary cells. Mol Cell Biol 1987, 7, 4075-4081.
15. Silverman JA, Raunio H, Gant TW, Thorgeirsson SS. Cloning and characterization of a member of the rat multidrug resistance (mdr) gene family. Gene 1991, 106, 229-236.
16. Deuchars KL, Duthie M, Ling V. Identification of distinct P-glycoprotein gene sequences in rat. Biochim Biophys Acta 1992, 1130, 157-165.
17. Van der Bliek AM, Baas F, Ten Houte de Lange T, Kooiman PM, Van der Velde-Koerts T, Borst P. The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J 1987, 6, 3325-3331.
18. Schinkel AH, Roelofs MEM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991, 51, 2628-2635.
19. Gros P, Raymond M, Bell J, Housman DE. Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol 1988, 8, 2770-2778.
20. Buschman E, Arceci RJ, Croop JM, et al. mdr2 encodes P-glycoprotein expressed in the bile canalicular membrane as determined by isoform-specific antibodies. J Biol Chem 1992, 267, 18093-18099.
21. Endicott JA, Sarangi F, Ling V. Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family. DNA Seq 1991, 2, 89-101.
22. Brown PC, Thorgeirsson SS, Silverman JA. Cloning and regulation of the rat mdr2 gene. Nucleic Acids Res 1993, 21, 3885-3891.
23. Furuya KN, Gebhardt R, Schuetz EG, Schuetz JD. Isolation of rat pgp3 cDNA: evidence for gender and zonal expression in the liver. Biochim Biophys Acta 1994, 1219, 636-644.
24. Gros P, Ben Neriah Y, Croop J, Housman DE. Isolation and characterization of a complementary DNA that confers multidrug resistance. Nature 1986, 323, 728-731.
25. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human 'MDR1' (P-glycoprotein) gene confers multidrug resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987, 84, 3004-3008.
26. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990, 38, 1277-1287.
27. van der Valk P, van Kalken CK, Ketelaars H, et al. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1990, 1, 56-64.
28. Smit JJM, Schinkel A, Mol CAAM, et al. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest 1994, 71, 638-649.
29. Smit JJM, Schinkel AH, Oude Elferink RPJ, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993, 75, 451-462.
30. Ruetz S, Gros P. Phospatidylcholine translocase: a physiological role for the mdr2 gene. Cell 1994, 77, 1071-1081.
31. Ruetz S, Gros P. Enhancement of Mdr2-mediated phosphatidylcholine translocation by the bile salt taurocholate. J Biol Chem 1995, 270, 25388-25395.
32. Oude Elferink RPJ, Groen AK. The role of mdr2 P-glycoprotein in biliary lipid secretion. Cross-talk between cancer research and biliary physiology. J Hepatol 1995, 23, 617-625.
33. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981, 41, 1967-1972.
34. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and Adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982, 42, 4730-4733.
35. Hyde SC, Emsley P, Hartshorn MJ, et al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance, and bacterial transport. Nature 1990, 346, 362-365.
36. Mimura CS, Holbrook SR, Ames GF-L. Structural model of the nucleotide-binding conserved component of periplasmic permeases. Proc Natl Acad Sci USA 1991, 88, 84-88.
37. Ames GF-L, Mimura CS, Holbrook SR, Shyamala V. Traffic ATPases: a superfamily of transport proteins operating from Escherichia coli to humans. Adv Enzymol 1992, 65, 1-47.
38. Higgins CF. ABC transporters - from microorganisms to man. Ann Rev Cell Biol 1992, 8, 67-113.
39. Higgins CF. The ABC of channel regulation. Cell 1995, 82, 693-696.
40. Higgins CF. The ABC transporter channel superfamily - an overview. Semin Cell Biol 1993, 4, 1-5.
41. Walker JE, Saraste M, Runswick MJ, Gay NJ. Distantly related sequences in the a- and b-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J 1982, 1, 945-951.
42. Shyamala V, Baichwald V, Beall E, Ames GF-L. Structure-function analysis of the histidine permease and comparison with cystic fibrosis mutations. J Biol Chem 1991, 266, 18714-18719.
43. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985, 316, 820-823.
44. Yoshimura A, Kuwazuru Y, Sumizawa T, et al. Cytoplasmic orientation and two-domain structure of the multidrug transporter, P-glycoprotein, demonstrated with sequence-specific antibodies. J Biol Chem 1989, 264, 16282-16291.
45. Georges E, Bradley G, Gariepy J, Ling V. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 1990, 87, 152-156.
46. Georges E, Tsuruo T, Ling V. Topology of P-Glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody. J Biol Chem 1993, 268, 1792-1798.
47. Cianfriglia M, Willingham MC, Tombesi M, Scagliotti GV, Frasca G, Chersi A. P-glycoprotein epitope mapping. II. The murine monoclonal antibody MM6.15 to human multidrug-resistant cells binds with three distinct loops in the MDR1-P-glycoprotein extracellular domain. Int J Cancer 1994, 56, 153-160.
48. Schinkel AH, Kemp S, Dolle M, Rudenko G, Wagenaar E. N-glycosylation and deletion mutants of the human MDR1 P-Glycoprotein. J Biol Chem 1993, 268, 7474-7481.
49. Zhang J-T, Ling V. Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. J Biol Chem 1991, 266, 18224-18232.
50. Zhang JT, Duthie M, Ling V. Membrane topology of the N-terminal half of the hamster P-glycoprotein molecule. J Biol Chem 1993, 268, 15101-15110.
51. Skach WR, Calayag MC, Lingappa VR. Evidence for an alternate model of human P-Glycoprotein structure and biogenesis. J Biol Chem 1993, 268, 6903-6908.
52. Skach WR, Lingappa VR. Amino-terminal assembly of human P-glycoprotein at the endoplasmic reticulum is directed by cooperative actions of two internal sequences. J Biol Chem 1993, 268, 23552-23561.
53. Skach WR, Lingappa VR. Transmembrane orientation and topogenesis of the third and fourth membrane-spanning regions of human P-glycoprotein (MDR1). Cancer Res 1994, 54, 3202-3209.
54. Bibi E, Béja O. Membrane topology of multidrug resistance protein expressed in Escherichia coli. N-terminal domain. J Biol Chem 1994, 269, 19910-19915.
55. Béja O, Bibi E. Multidrug resistance protein (Mdr)-alkaline phosphatase hybrids in Escherichia coli suggest a major revision in the topology of the C-terminal half of Mdr. J Biol Chem 1995, 270, 12351-12354.
56. Loo TW, Clarke DM. Membrane topology of a cysteine-less mutant of human P-glycoprotein. J Biol Chem 1995, 270, 843-848.
57. Kast C, Canfield V, Levenson R, Gros P. Membrane topology of P-glycoprotein as determined by epitope insertion: transmembrane organization of the N-terminal domain of mdr3. Biochemistry 1995, 34, 4402-4411.
58. Azzaria M, Schurr E, Gros P. Discrete mutations introduced in the predicted nucleotide-binding sites of the mdr1 gene abolish its ability to confer multidrug resistance. Mol Cell Biol 1989, 9, 5289-5297.
59. Bibi E, Gros P, Kaback HR. Functional expression of mouse mdrl in Escherichia coli. Proc Natl Acad Sci USA 1993, 90, 9209-9213.
60. Friedlander M, Blobel G. Bovine opsin has more than one signal sequence. Nature 1985, 318, 338-343.
61. Wessels HP, Spiess M. Insertion of a multispanning membrane protein occurs sequentially and requires only one signal sequence. Cell 1988, 55, 61-70.
62. Zhang J-T, Ling V. Involvement of cytoplasmic factors regulating the membrane orientation. Biochemistry 1995, 34, 9159-9165.
63. Loo TW, Clarke DM. P-glycoprotein: associations between domains and molecular chaperones. J Biol Chem 1995, 270, 21839-21844.
64. Wright LC, Dyne M, Holmes KT, Mountford CE. Phospholipid and ether linked phospholipid content alter with cellular resistance to vinblastine. Biochem Biophys Res Commun 1985, 133, 539-545.
65. Arsenault AL, Ling V, Kartner N. Altered plasma membrane ultrastructure in multidrug-resistant cells. Biochim Biophys Acta 1988, 938, 315-321.
66. Boscoboinik D, Debanne MT, Stafford AR, Jung CY, Gupta RS, Epand RM. Dimerization of the P-glycoprotein in membranes. Biochim Biophys Acta 1990, 1027, 225-228.
67. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS. P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 1990, 21, 34-48.
68. Naito M, Tsuruo T. Functionally active homodimer of P-glycoprotein in multidrug-resistant tumor cells. Biochem Biophys Res Commun 1992, 185, 284-290.
69. Poruchinsky MS, Ling V. Detection of oligomeric and monomeric forms of P-glycoprotein in multidrug resistant cells. Biochemistry 1994, 33, 4163-4174.
70. Willingham MC, Richert ND, Cornwell MM, et al. Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. J Histochem Cytochem 1987, 35, 1451-1456.
71. Germann UA, Willingham MC, Pastan I, Gottesman MM. Expression of the human multidrug transporter in insect cells by a recombinant baculovirus. Biochemistry 1990, 29, 2295-2303.
72. Kuchler K, Thorner J. Functional expression of human mdr1 in the yeast Saccharomyces cerevisiae. Proc Natl Acad Sci USA 1992, 89, 2303-2306.
73. Evans GL, Ni B, Hrycyna CA, et al. Heterologous expression systems for P-glycoprotein: E. coli, yeast, and baculovirus. J Bioenerget Biomem 1995, 27, 43-52.
74. Loo TW, Clarke DM. Prolonged association of temperature-sensitive mutants of human P-glycoprotein with calnexin during biogenesis. J Biol Chem 1994, 269, 28683-28689.
75. Carlsen SV, Till JE, Ling V. Modulation of drug permeability in Chinese hamster ovary cells. Possible role for phosphorylation of surface glycoproteins. Biochim Biophys Acta 1977, 467, 238-250.
76. Richert ND, Aldwin L, Nitecki D, Gottesman MM, Pastan I. Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells. Biochemistry 1988, 27, 7607-7613.
77. Greenberger LM, Lothstein L, Williams SS, Horwitz SB. Distinct P-glycoprotein precursors are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA 1988, 85, 3762-3766.
78. Bruggemann EP, Germann UA, Gottesman MM, Pastan I. Two different regions of P-glycoprotein are photoaffinity labeled by azidopine. J Biol Chem 1989, 264, 15483-15488.
79. Endicott JA, Sarangi F, Ling V. Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family. DNA Seq 1991, 2, 89-101.
80. Van der Bliek AM, Kooiman PM, Schneider C, Borst P. Sequence of mdr3 cDNA, encoding a human P-glycoprotein. Gene 1988, 71, 401-411.
81. Bruggemann EP, Currier SJ, Gottesman MM, Pastan I. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem 1992, 267, 21020-21026.
82. Saeki T, Shimabuku AM, Azuma Y, Shibano Y, Komano T, Ueda T. Expression of human P-glycoprotein in yeast cells - effects of membrane component sterols on the activity of P-glycoprotein. Agric Biol Chem 1991, 55, 1859-1865.
83. Raymond M, Gros P, Whiteway M, Thomas DY. Functional complementation of yeast ste6 by a mammalian multidrug resistance mdr gene. Science 1992, 256, 232-234.
84. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992, 267, 4854-4858.
85. Ling V, Kartner N, Sudo T, Siminovitch L, Riordan JR. The multidrug resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 1983, 67, 869-874.
86. Kramer R, Weber TK, Morse B, et al. Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. Br J Cancer 1993, 67, 959-968.
87. Chou TH-H, Kessel D. Effects of tunicamycin treatment on anthracycline resistance in P388 murine leukemia cells. Biochem Pharmacol 1981, 30, 3134-3136.
88. Beck WT, Cirtain M. Continued expression of Vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase. Cancer Res 1982, 42, 184-189.
89. Ichikawa M, Yoshimura A, Furukawa T, Sumizawa T, Nakazima Y, Akiyama S-I. Glycosylation of P-glycoprotein in a multidrug-resistant KB cell line, and in human tissues. Biochim Biophys Acta 1991, 1073, 309-315.
90. Kramer R, Weber TK, Arceci R, et al. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer 1995, 71, 670-675.
91. Germann UA, Chambers T, Ambudkar SV, Pastan I, Gottesman MM. Effects of phosphorylation on multidrug resistance. J Bioenerget Biomem 1995, 27, 53-61.
92. Chambers TC. Phosphorylation of proteins involved in multidrug resisance. In Gupta S, Tsuruo T, ed. Multidrug Resistance in Cancer Cells. Chichester, U.K., John Wiley & Sons, 1996, in press.
93. Schurr E, Raymond M, Bell JC, Gros P. Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA. Cancer Res 1989, 49, 2729-2734.
94. Center MS. Evidence that adriamycin resistance in Chinese hamster lung cells is regulated by phosphorylation of a plasma membrane glycoprotein. Biochem Biophys Res Commun 1983, 115, 159-166.
95. Hamada H, Hagiwara K-I, Nakajima T, Tsuruo T. Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res 1987, 47, 2860-2865.
96. Fine RL, Patel J, Chabner BA. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 1988, 85, 582-586.
97. Chambers TC, McAvoy EM, Jacobs JW, Eilon G. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 1990, 265, 7679-7686.
98. Chambers TC, Zheng B, Kuo JF. Regulation by phorbol ester and protein kinase-C inhibitors, and by a protein phosphatase inhibitor (okadaic acid), of P-glycoprotein phosphorylation and relationship to drug accumulation in multidrug-resistant human-KB cells. Mol Pharmacol 1992, 41, 1008-1015.
99. Yu G, Ahmad S, Aquino A, et al. Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun 1991, 3, 181-188.
100. Bates SE, Currier SJ, Alvarez M, Fojo AT. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 1992, 31, 6366-6372.
101. Bates SE, Lee JS, Dickstein B, Spolyar M, Fojo AT. Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry 1993, 32, 9156-9164.
102. Aftab DT, Yang JM, Hait WN. Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. Oncol Res 1994, 6, 59-70.
103. Ma L, Marquard D, Takemoto L, Center MS. Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. J Biol Chem 1991, 266, 5593-5599.
104. Chaudhary PM, Roninson IB. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase-C agonists. Oncol Res 1992, 4, 281-290.
105. Sampson KE, Wolf CL, Abraham I. Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Cancer Lett 1993, 68, 7-14.
106. Sato W, Yusa K, Naito M, Tsuruo T. Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem Biophys Res Commun 1990, 173, 1252-1257.
107. Miyamoto KI, Wakusawa S, Inoko K, Takagi K, Koyama M. Reversal of vinblastine resistance by a new staurosporine derivative, NA-382, in P388/ADR cells. Cancer Lett 1992, 64, 177-183.
108. Wakusawa S, Nakamura S, Tajima K, Miyamoto KI, Hagiwara M, Hidaka H. Overcoming of vinblastine resistance by isoquinoline sulfonamide compounds in adriamycin-resistant leukemia cells. Mol Pharmacol 1992, 41, 1034-1038.
109. Wakusawa S, Inoko K, Miyamoto K, et al. Staurosporine derivatives reverse multidrug resistance without correlation with their protein kinase inhibitory activities. J Antibiot 1993, 46, 353-355.
110. Smith CA, Zilfou JT. Circumvention of P-glycoprotein-mediated multipledrug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 1995, 270, 28145-28152.
111. Gupta S, Patel K, Singh H, Gollapudi S. Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein. Cancer Lett 1994, 76, 139-145.
112. Sachs CW, Safa AR, Harrison SD, Fine RL. Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem 1995, 270, 26639-26648.
113. Gupta KP, Ward NE, Garvitt KR, Bergman PJ, O'Brian CO. Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-α pseudosubstrate peptide. J Biol Chem, in press.
114. Staats J, Marquardt D, Center MS. Characterization of a membrane-associated protein kinase of multidrug-resistant HL60 cells which phosphorylates P-glycoprotein. J Biol Chem 1990, 265, 4084-4090.
115. Sampson KE, McCroskey MC, Abraham I. Identification of a 170-kDa membrane kinase with increased activity in KB-V1 multidrug resistant cells. J Cell Biochem 1993, 52, 384-395.
116. Chambers TC, Germann UA, Gottesman MM, Pastan I, Kuo JF, Ambudkar SV. Bacterial expression of the linker region of human MDR1 P-glycoprotein and mutational analysis of phosphorylation sites. Biochemistry 1995, 34, 14156-14162.
117. Mellado W, Horwitz SB. Phosphorylation of the multidrug resistance associated glycoprotein. Biochemistry 1987, 26, 6900-6904.
118. Chambers TC, Pohl J, Raynor RL, Kuo JF. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase-C. J Biol Chem 1993, 268, 4592-4595.
119. Chambers TC, Pohl J, Glass DB, Kuo JF. Phosphorylation by protein kinase C and cyclic AMP-dependent protein kinase of synthetic peptides derived from the linker region of human P-glycoprotein. Biochem J 1994, 299, 309-315.
120. Aftab DT, Yang JM, Hait WN. Functional role of phosphorylation. Oncol Res 1994, 6, 59-70.
121. Ahmad S, Glazer RI. Expression of the antisense cDNA for protein kinase-C-alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol 1993, 43, 858-862.
122. Ahmad S, Safa AR, Glazer RI. Modulation of P-glycoprotein by protein kinase C alpha in a baculovirus expression system. Biochemistry 1994, 33, 10313-10318.
123. Orr GA, Han EK-H, Browne PC, et al. Identification of the major phosphorylation domain of murine mdrlb P-glycoprotein. J Biol Chem 1993, 268, 25054-25062.
124. Riordan JR, Rommens JM, Kerem B-S, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989, 245, 1066-1073.
125. Cheng SH, Rich DP, Marshall J, Gregory RJ, Welsh MJ, Smith AE. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 1991, 66, 1027-1036.
126. Chang X-B, Tabcharani JA, Hou Y-X, et al. Protein kinase A (PKA) still activates CFTR chloride channel after mutagenesis of all 10 PKA consensus phosphorylation sites. J Biol Chem 1993, 268, 11304-11311.
127. Germann UA, Chambers TC, Ambudkar SV, et al. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem, in press.
128. Scala S, Dickstein B, Regis J, Szallasi Z, Blumberg PM, Bates SE. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Clin Cancer Res 1995, 1, 1581-1587.
129. Sampson KE, Wolf CL, Abraham I. Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance. Cancer Lett 1993, 68, 7-14.
130. Hardy SP, Goodfellow HR, Valverde MA, Gill DR, Sepulveda V, Higgins CF. Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBO J 1995, 14, 68-75.
131. Higgins CF. P-glycoprotein and cell volume-activated chloride channels. J Bioenerget Biomemb 1995, 27, 63-70.
132. Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 1989, 49, 5002-5006.
133. Tamai I, Safa AR. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 1991, 266, 16796-16800.
134. Naito M, Tsuge H, Kuroko C, et al. Enhancement of cellular accumulation of cyclosporine by anti-P-glycoprotein monoclonal antibody MRK-16 and synergistic modulation of multidrug resistance. J Natl Cancer Inst 1993, 85, 311-316.
135. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993, 268, 6077-6080.
136. Ueda K, Okamura N, Hirai M, et al. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 1992, 267, 24248-24252.
137. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. P-Glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Lett 1993, 324, 99-102.
138. Cornwell MM, Gottesman MM, Pastan I. Increased vinblastine binding to membrane vesicles from multidrug resistant KB cells. J Biol Chem 1986, 262, 7921-7928.
139. Cornwell MM, Safa AR, Felsted RL, Gottesman MM, Pastan I. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150-170kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci USA 1986, 83, 3847-3850.
140. Safa AR, Glover CJ, Meyets MB, Biedler JL, Felsted RL. Vinblastine photoaffinity labeling of a high-molecular-weight surface membrane glycoprotein specific for multidrug-resistant cells. J Biol Chem 1986, 261, 6137-6140.
141. Safa AR, Mehta ND, Agresti M. Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells with photoactive analogs of colchicine. Biochem Biophys Res Commun 1989, 161, 1402-1408.
142. Safa AR, Stern RK, Choi K, et al. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly to Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA 1990, 87, 7225-7229.
143. Safa AR. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc Natl Acad Sci USA 1988, 85, 7187-7191.
144. Busche R, Tummler B, Riordan JR, Cano-Gauci DF. Preparation and utility of a radioiodinated analogue of daunomycin in the study of multidrug resistance. Mol Pharmacol 1989, 35, 414-421.
145. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL. Identification of the multidrug-resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 1987, 262, 7884-7888.
146. Akiyama S-i, Cornwell MM, Kuwano M, Pastan I, Gottesman MM. Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. Mol Pharmacol 1988, 33, 144-147.
147. Greenberger LM, Yang CH, Gindin E, Horwitz SB. Photoaffinity probes for the alpha 1-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein. J Biol Chem 1990, 265, 4394-4401.
148. Morris DI, Speicher LA, Ruoho AE, Tew KD, Seamon KB. Interaction of forskolin with the P-glycoprotein multidrug transporter. Biochemistry 1991, 30, 8371-8379.
149. Greenberger LM, Lisanti CJ, Silva JT, Horwitz SB. Domain mapping of the photoaffinity drug-binding sites in P-glycoprotein encoded mouse mdr1b. J Biol Chem 1991, 266, 20744-20751.
150. Borchers C, Ulrich WR, Klemm K, et al. B9209-005, an azido derivative of the chemosensitizer dexniguldipine-HCl, photo-labels P-glycoprotein. Mol Pharmacol 1995, 48, 21-29.
151. Beck WT, Qian X-D. Photoaffinity substrates for P-glycoprotein. Biochem Pharmacol 1992, 43, 89-93.
152. Safa AR. Photoaffinity labeling of P-glycoprotein in multidrug resistant cells. Cancer Invest 1993, 11, 46-56.
153. Greenberger LM. Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domain-6 and domain-12. J Biol Chem 1993, 268, 11417-11425.
154. Morris DI, Greenberger LM, Bruggemann EP, et al. Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. Mol Pharmacol 1994, 46, 329-337.
155. Ferry DR, Russell MA, Cullen MH. P-glycoprotein possesses a 1,4-dihydropyridine-selective drug acceptor site which is allosterically coupled to a vinca-alkaloid-selective binding site. Biochem Biophys Res Commun 1992, 188, 440-445.
156. Ferry DR, Malkhandi PJ, Russel MA, Kerr DJ. Allosteric regulation of [3H]vinblastine binding to P-glycoprotein of MCF-7 ADR cells by dexniguldipine. Biochem Pharmacol 1995, 49, 1851-1861.
157. Loo TW, Clark DM. Reconstitution of drug-stimulated ATPase activity following co-expression of each half of human P-glycoprotein as separate polypeptides. J Biol Chem 1994, 269, 7750-7755.
158. Currier SJ, Ueda K, Willingham MC, Pastan I, Gottesman MM. Deletion and insertion mutants of the multidrug transporter. J Biol Chem 1989, 264, 14376-14381.
159. Choi K, Chen C-J, Kriegler M, Roninson IB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 1989, 53, 519-529.
160. Kioka N, Tsubota J, Kakehi Y, et al. P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Glyl85 with, an altered pattern of multidrug resistance. Biochem Biophys Res Commun 1989, 162, 224-231.
161. Gros P, Dhir R, Croop J, Talbot F. A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc Natl Acad Sci USA 1991, 88, 7289-7293.
162. Currier SJ, Kane SE, Willingham MC, Cardarelli CO, Pastan I, Gottesman MM. Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporters. J Biol Chem 1992, 267, 25153-25159.
163. Devine SE, Ling V, Melera PW. Amino acid substitutions in the 6th transmembrane domain of P-glycoprotein alter multidrug resistance. Proc Natl Acad Sci USA 1992, 89, 4564-4568.
164. Loo TW, Clarke DM. Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. J Biol Chem 1993, 268, 3143-3149.
165. Loo TW, Clarke DM. Functional consequences of phenylalanine mutations in the predicted transmembrane domain of P-glycoprotein. J Biol Chem 1993, 268, 19965-19972.
166. Loo TW, Clarke DM. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein. Biochemistry 1994, 33, 14049-14057.
167. Loo TW, Clarke DM. Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. J Biol Chem 1994, 269, 7243-7248.
168. Buschman E, Gros P. Functional analysis of chimeric genes obtained by exchanging homologous domains of the mouse mdrl and mdr2 genes. Mol Cell Biol 1991, 11, 595-603.
169. Beaudet L, Gros P. Functional dissection of P-glycoprotein nucleotide binding domains in chimeric and mutant proteins. J Biol Chem 1995, 270, 17159-17170.
170. Dhir R, Gros P. Functional analysis of chimeric proteins constructed by exchanging homologous domains of two P-glycoproteins conferring distinct drug resistance profiles. Biochemistry 1992, 31, 6103-6110.
171. Zhang X, Collins KI, Greenberger LM. Functional evidence that transmembrane 12 and the loop between transmembrane 11 and 12 form part of the drug-binding domain in P-glycoprotein encoded by MDR1. J Biol Chem 1995, 270, 5441-5448.
172. Tang-Wai DF, Kajiji S, DiCapua F, de Graaf D, Roninson IB, Gros P. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 1995, 34, 32-39.
173. Devine SE, Melera PW. Diversity of multidrug resistance in mammalian cells. J Biol Chem 1994, 269, 6133-6139.
174. Kajiji S, Talbot F, Grizzuti K, et al. Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain-11 as a putative drug binding site. Biochemistry 1993, 32, 4185-4194.
175. Kajiji S, Dreslin JA, Grizzuti K, Gros P. Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine 939/941. Biochemistry 1994, 33, 5041-5048.
176. Hoof T, Demmer A, Hadam MR, Riordan JR, Tummler B. Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1. J Biol Chem 1994, 269, 20575-20583.
177. Danø K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochem Biophys Acta 1973, 323, 466-483.
178. Cornwell MM, Tsuruo T, Gottesman MM, Pastan I. ATP-binding properties of P-glycoprotein from multidrug resistant KB cells. FASEB J 1987, 1, 51-54.
179. Cornwell MM, Pastan I, Gottesman MM. Binding of drugs and ATP by P-glycoprotein and transport of drugs by vesicles from human multidrug-resistant cells. In Roninson IB, ed. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York, Plenum Publishing Corporation, 1991, 229-242.
180. Al-Shawi MK, Senior AE. Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein. J Biol Chem 1993, 268, 4197-4206.
181. Baubichon-Cortay H, Baggetto LG, Dayan G, Di Pietro A. Overexpression and purification of the carboxyl-terminal nucleotide-binding domain from mouse P-glycoprotein. J Biol Chem 1994, 269, 22983-22989.
182. Sharma S, Rose D. Cloning, overexpression, purification, and characterization of the carboxyl-terminal nucleotide binding domain of P-glycoprotein. J Biol Chem 1995, 270, 14085-14093.
183. Shimabuku AM, Nishimoto T, Ueda K, Komano T. P-glycoprotein - ATP hydrolysis by the N-terminal nucleotide-binding domain. J Biol Chem 1992, 267, 4308-4311.
184. Müller M, Bakos E, Welker E, et al. Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein. J Biol Chem, in press.
185. Urbatsch IL, Sankaran B, Weber J, Senior AE. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J Biol Chem 1995, 270, 19393-19390.
186. Urbatsch IL, Sankaran B, Bhagat S, Senior AE. Both P-glycoprotein nucleotide binding sites are catalytically active. J Biol Chem 1995, 270, 26956-26961.
187. Senior AE, Al-Shawi MK, Urbatsch IL. ATP hydrolysis by multidrug-resistance protein from Chinese Hamster ovary cells. J Bioenerget Biomemb 1995, 27, 31-36.
188. Scarborough GA. Drug-stimulated ATPase activity of the human P-glycoprotein. J Bioenerget Biomemb 1995, 27, 37-41.
189. Shapiro AB, Ling V. Using purified P-glycoprotein to understand multidrug resistance. J Bioenerget Biomemb 1995, 27, 7-13.
190. Sharom F. Characterization and functional reconstitution of the multidrug transporter. J Bioenerget Biomemb 1995, 27, 15-22.
191. Ambudkar SV. Purification and reconstitution of functional human P-glycoprotein. J Bioenerget Biomemb 1995, 27, 23-29.
192. Hamada H, Tsuruo T. Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance - 170- to 180-kilodalton membrane glycoprotein is an ATPase. J Biol Chem 1988, 263, 1454-1458.
193. Hamada H, Tsuruo T. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res 1988, 48, 4926-4932.
194. Homoloya L, Holló Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993, 268, 21493-21496.
195. Sarkadi B, Müller M, Homoloya L, et al. Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB J 1994, 8, 766-770.
196. Rao US, Scarborough GA. Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol 1994, 45, 773-776.
197. Rao US, Fine RL, Scarborough GA. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 1994, 48, 287-292.
198. Garrigos M, Belehradek JJ, Mir LM, Orlowski S. Absence of cooperativity for MgATP and verapamil effects on the ATPase activity of P-glycoprotein containing membrane vesicles. Biochem Biophys Res Commun 1993, 196, 1034-1041.
199. Al-Shawi MK, Urbatsch IL, Senior AE. Covalent inhibitors of P-glycoprotein ATPase activity. J Biol Chem 1994, 269, 8986-8992.
200. Sharom FJ, DiDiodato G, Yu X, Ashbourne KJD. Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores. J Biol Chem 1995, 270, 10334-10341.
201. Doige CA, Yu XH, Sharom FJ. ATPase activity of partially purified P-glycoprotein from multidrug-resistant Chinese hamster ovary cells. Biochim Biophys Acta 1992, 1109, 149-160.
202. Doige CA, Yu X, Sharom FJ. The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim Biophys Acta 1993, 1146, 65-72.
203. Ambudkar SV, Lelong IH, Zhang JP, Cardarelli CO, Gottesman MM, Pastan I. Partial purification and reconstitution of the human multidrug-resistance pump - characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci USA 1992, 89, 8472-8476.
204. Sharom FJ, Yu X, Doige CA. Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. J Biol Chem 1993, 268, 24197-24202.
205. Urbatsch IL, Al-Shawi MK, Senior AE. Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry 1994, 33, 7069-7076.
206. Shapiro AB, Ling V. ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. J Biol Chem 1994, 269, 3745-3754.
207. Naito M, Tsuruo T. Reconstitution of purified P-glycoprotein into liposomes. J Cancer Res Clin Oncol 1995, 21, 582-586.
208. Yang C-PH, Cohen D, Greenberger LM, Hsu SI-H, Horwitz SB. Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem 1990, 265, 10282-10288.
209. Urbatsch IL, Senior AE. Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein. Arch Biochem Biophys 1995, 316, 135-140.
210. Sharom FJ, Yu X, Chu JWK, Doige CA. Characterization of the ATPase activity of P-glycoprotein from multidrug resistant Chinese hamster ovary cells. Biochem J 1995, 308, 381-390.
211. Rao US. Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. J Biol Chem 1995, 270, 6686-6690.
212. Loo TW, Clarke DM. Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities. J Biol Chem 1995, 270, 21449-21452.
213. Welker E, Szabó K, Holló Z, Müller M, Sarkadi B, Váradi A. Drug-stimulated ATPase activity of a deletion mutant of the human multidrug resistance protein (MDR1). Biochem Biophys Res Commun 1995, 216, 602-609.
214. Ling V, Thompson LH. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 1974, 83, 103-116.
215. Stein WD, Cardarelli CO, Pastan I, Gottesman MM. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol 1994, 45, 763-772.
216. Roepe PD. Analysis of the steady-state and initial rate of doxorubicin efflux from a series of multidrug-resistant cells expressing different levels of P-glycoprotein. Biochemistry 1992, 31, 12555-12564.
217. Roepe PD, Wei LY, Cruz J, Carlson D. Lower electrical membrane potential and altered pH(i) homeostasis in multidrug-resistant (MDR) cells - further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 1993, 32, 11042-11056.
218. Roepe PD, Weisburg JH, Luz JG, Hoffman MM, Wei L-Y. Novel Cl(-)-dependent intracellular pH regulation in murine MDR 1 transfectants and potential implications. Biochemistry 1994, 33, 11008-11015.
219. Luz JG, Wei L-Y, Basu S, Roepe PD. Transfection of mu MDR 1 inhibits Na(+)-independent Cl-/-HCO3 exchange in Chinese hamster ovary cells. Biochemistry 1994, 33, 7239-7249.
220. Keizer HG, Joenje H. Unknown - pH. Increased cytosolic pH in multidrug-resistant human lung tumor cells: effect of verapamil. J Natl Cancer Inst 1989, 81, 706-709.
221. Thiebaut F, Currier SJ, Whitabker J, et al. Activity of the multidrug transporter results in alkalinization of the cytosol: measurement of cytosolic pH by microinjection of a pH-sensitive dye. J Histochem Cytochem 1990, 38, 685-690.
222. Boscoboinik D, Gupta RS, Epand RM. Investigation of the relationship between altered intracellular pH and multidrug resistance in mammalian cells. Br J Cancer 1990, 61, 568-572.
223. Wei L-Y, Roepe PD. Low external pH and osmotic shock increase the expression of human MDR protein. Biochemistry 1994, 33, 7229-7238.
224. Hasmann M, Valet GK, Tapiero H, Trevorrow K, Lampidis T. Membrane potential differences between adriamycin-sensitive and -resistant cells as measured by flow cytometry. Biochem Pharmacol 1989, 38, 305-312.
225. Simon S, Roy D, Schindler M. Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA 1994, 91, 1128-1132.
226. Altenberg GA, Young G, Horton JK, Glass D, Belli JA, Reuss L. Changes in intracellular or extracellular pH do not mediate P-glycoprotein-dependent multidrug resistance. Proc Natl Acad Sci USA 1993, 90, 9735-9738.
227. Altenberg GA, Vanoye CG, Han ES, Deitmer JW, Reuss L. Relationships between rhodamine 123 transport, cell volume, and ion-channel function of P-glycoprotein. J Biol Chem 1994, 269, 7145-7149.
228. Borrel MN, Pereira E, Fiallo M, Garnier-Suillerot A. Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4′-O-tetrahydropyranyl-adriamycin incorporation in K562 drug-resistant cells. Eur J Biochem 1994, 223, 125-133.
229. Ruetz S, Gros P. Functional expression of P-glycoprotein in secretory vesicles. J Biol Chem 1994, 269, 12277-12284.
230. Abraham EH, Prat AG, Gerweck L, et al. The multidrug resistance (mdr1) gene product functions as an ATP channel. Proc Natl Acad Sci USA 1993, 90, 312-316.
231. Ruetz S, Raymond M, Gros P. Functional expression of P-glycoprotein encoded by the mouse mdr3 gene in yeast cells. Proc Natl Acad Sci USA 1993, 90, 11588-11592.
232. Lankelma J, Spoelstra EC, Dekker H, Broxterman HJ. Evidence for daunomycin efflux from multidrug-resistant 2780AD human ovarian carcinoma cells against a concentration gradient. Biochim Biophys Acta 1990, 1055, 217-222.
233. Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 1988, 85, 3580-3584.
234. Kamimoto Y, Gatmaitan Z, Hsu J, Arias IM. The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem 1989, 264, 11693-11698.
235. Lelong IH, Padmanabhan R, Lovelace E, Pastan I, Gottesman MM. ATP and GTP as alternative energy sources for vinblastine transport by P-170 in KB-V1 plasma membrane vesicles. FEBS Lett 1992, 304, 256-260.
236. Hsing S, Gatmaitan Z, Arias IM. The function of Gp170, the multidrug resistance gene product, in the brush border of rat intestinal mucosa. Gastroenterology 1992, 102, 879-885.
237. Doige CA, Sharom FJ. Transport properties of P-Glycoprotein in plasma membrane vesicles from multidrug-resistant Chinese hamster ovary cells. Biochim Biophys Acta 1992, 1109, 61-171.
238. Guiral M, Viratelle O, Westerhoff HV, Lankelma J.Cooperative P-glycoprotein mediated daunorubicin transport into DNA-loaded plasma membrane vesicles. FEBS Lett 1994, 346, 141-145.
239. Schlemmer SR, Sirotnak FM. Functional studies of P-glycoprotein in inside-out plasma membrane vesicles derived from murine erythroleukemia cells overexpressing MDR 3. Properties and kinetics of the interaction of vinblastine with P-glycoprotein and evidence for its active mediated transport. J Biol Chem 1994, 269, 31059-31066.
240. Shapiro AB, Ling V. Reconstitution of drug transport by purified P-glycoprotein. J Biol Chem 1995, 270, 16167-16175.
241. Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Pharmacol Sci 1992, 17, 18-21.
242. Gottesman MM, Willingham MC, Theibaut F, Pastan I. Expression of the MDR1 gene in normal human tissues. In Roninson IB, ed. Molecular and Cellular Biology of Multidrug Resistance in Tumors. New York, Plenum Publishing Corporation, 1991, 279-289.
243. Cordon-Cardo C. Immunohistochemical analysis of P-glycoprotein expression in normal and tumor tissues in humans. In Roninson IB, ed. Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. New York, Plenum Publishing Corporation, 1991, 303-318.
244. Chaudhary, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66, 85-94.
245. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987, 84, 265-269.
246. Chin JE, Chen C-J, Kriegler M, Roninson IB. Structure and expression of die human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989, 9, 3808-3820
247. Borst P, Schinkel AH, Smit JJM, et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1995, 60, 289-299.
248. Croop JM, Raymond M, Harber D, et al. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol 1989, 9, 1346-1350.
249. Teeter LD, Becker FF, Chisari W, Li D, Kuo MT. Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol 1990, 10, 5728-5735.
250. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987, 84, 7735-7738.
251. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein, P170: evidence for localization in brain capillaries and cross-reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989, 37, 159-164.
252. Cordon-Cardo C, O'Brian JP, Casals D, et al. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at the blood-brain barrier sites. Proc Natl Acad Sci USA 1989, 86, 695-698.
253. Arceci RJ, Croop JM, Horwitz SB, Housman DE. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988, 85, 4350-4354.
254. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992, 80, 2735-2739.
255. Licht T, Pastan I, Gottesman MM, Herrmann F. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann Hematol 1994, 69, 159-171.
256. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491-502.
257. Schinkel AH, Wagenaar E, Van Deemter L, Mol CAA, Borst P. Absence of mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporine A. J Clin Invest 1995, 96, 1698-1705.
258. Tatsuta T, Naito M, Oh-Hara T, Sugawara I, Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992, 267, 20383-20391.
259. Tanigawara Y, Okamura N, Hirai M, et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992, 263, 840-845.
260. Arias IM. Cyclosporin, the biology of the bile canaliculus, and cholestasis. Gastroenterology 1993, 104, 1558-1560.
261. Leveille-Webster CR, Arias IM. The biology of the P-glycoproteins. J Membrane Biol 1995, 143, 89-102.
262. Axiotis CA, Guarch R, Merino MJ, Lapone N, Neumann RD. P-glycoprotein expression is increased in human secretory and gestational endometrium. Lab Invest 1991, 65, 577-581.
263. Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 1988, 48, 1926-1929.
264. Ueda K, Saeki T, Hirai M, et al. Human P-glycoprotein as a multi-drug transporter analyzed by using transepithelial transport system. Jpn J Physiol 1994, 44, S67-S71.
265. Wolf DC, Horwitz SB. P-Glycoprotein transports cortico-sterone and is photoaffinity-labeled by the steroid. Int J Cancer 1992, 52, 141-146.
266. Chin K-V, Chauhan SS, Abraham I, et al. Reduced mRNA levels for the multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines. J Cell Physiol 1992, 152, 87-94.
267. Piekarz RL, Cohen D, Horwitz SB. Progesterone regulates the murine multidrug resistance mdr1b gene. J Biol Chem 1993, 268, 7613-7616.
268. Altuvia S, Stein WD, Goldenberg S, Kane SE, Pastan I, Gottesman MM. Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance mdr gene expression. J Biol Chem 1993, 268, 27127-27132.
269. Michaelis S. STE6, the yeast a-factor transporter. Semin Cell Biol 1993, 4, 17-27.
270. Koronakis V, Hughes C, Koronakis E. ATPase activity and ATP/ADP-induced conformational change in the soluble domain of the bacterial protein translocator HlyB. Mol Microbiol 1993, 8, 1163-1175.
271. Shepherd JC, Schumacher TNM, Ashtonrickardt PG, et al. TAP1-Dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell 1993, 74, 577-584.
272. Sharma RC, Inoue S, Roitelman J, Schimke RT, Simoni RD. Peptide transport by the multidrug resistance pump. J Biol Chem 1992, 267, 5731-5734.
273. Sarkadi B, Muller M, Homolya L, et al. Interaction of bioactive hydrophobic peptides with the human multidrug transporter. FASEB J 1994, 8, 766-70.
274. Valverde MA, Diáz M, Sepúlveda FV, Gill DR, Hyde SC, Higgins CF. Volume-regulated chloride channels associated with the human multidrug resistance P-glycoprotein. Nature 1992, 355, 830-833.
275. Gill DR, Hyde SC, Higgins CF, Valverde MA, Mintenig GM, Sepúlveda FV. Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell 1992, 71, 23-32.
276. Altenberg GA, Deitmer JW, Glass DC, Ruess L. P-glycoprotein-associated Cl-currents are activated by cell swelling but do not contribute to cell volume regulation. Cancer Res 1994, 54, 618-622.
277. Zhang JJ, Jacob TJC, Valverde MA, et al. Tamoxifen blocks chloride channels. A possible mechanism for cataract formation. J Clin Invest 1994, 94, 1690-1697.
278. Rasola A, Galietta LJV, Gruenert DC, Romeo G. Volume-sensitive chloride currents in four epithelial cell lines are not directly correlated to the expression of the MDR-1 gene. J Biol Chem 1994, 269, 1432-1436.
279. Dong Y, Chen C, Duran GE, et al. Volume-activated chloride current is not related to P-glycoprotein overexpression. Cancer Res 1994, 54, 5029-5032.
280. Germann UA. Molecular analysis of the multidrug transporter. Cytotechnology 1993, 12, 33-62.